To assess serum levels of CitH3 in patients with septic and non-septic shock and study its correlation with the severity of septic shock, specifically focusing on its predictive value for patient outcomes.
Key Findings:
Citrullinated histone H3 (CitH3) levels are elevated in septic patients and correlate with illness severity, organ dysfunction, and mortality, establishing it as a more specific biomarker than procalcitonin.
CitH3 serves as a specific biomarker for severe sepsis and septic shock, reflecting systemic inflammatory response.
Interpretation:
Elevated CitH3 levels indicate severe cellular injury and systemic inflammation, making it a potential biomarker for diagnosing and predicting outcomes in septic shock, which could guide clinical decision-making.
Limitations:
The study was limited to a small sample size and a single center, which may affect the generalizability of the findings.
Exclusion of patients with certain conditions, such as those on immunosuppressive therapy, may limit the applicability of results to broader patient populations.
Conclusion:
Citrullinated histone H3 is a promising biomarker for diagnosing septic shock and predicting patient outcomes, warranting further research to validate its clinical utility.
